First-in-human Study of UX016 in GNEM
Study sponsor: Ultragenyx Pharmaceutical Inc · RARE
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-12Estimated
Enrollment · participants24Estimated
Source updated2026-10-13Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.